Masahiko Tokuda’s Post

Data-driven decisions are key in the healthcare industry. Did you know the Brazilian market is projected to grow by 9.8% this year? This surge, coupled with a complex public-private healthcare system, presents a unique opportunity for pharmaceutical companies. In our latest article, written by Dr. Fisiologia on behalf of Pharma Meeting Brazil, we discuss more about all Brazil's advantages for foreign pharmaceutical companies. Download now to read the full article here: https://lnkd.in/dMwapyDv

Drug product life cycle management refers to the strategic and dynamic process through which pharmaceutical companies optimize the entire life span of a medicinal product, from its initial development and regulatory approval to its eventual obsolescence. This comprehensive approach involves a series of coordinated activities, encompassing continuous research and development, clinical trials, market launch, post-marketing surveillance, and eventual phase-out or reformulation. By embracing a well-structured life cycle management strategy, pharmaceutical companies can adapt to changing market dynamics, address emerging patient needs, comply with evolving regulations, and extend the commercial viability of their products, ultimately enhancing patient outcomes and sustaining business growth in the highly competitive pharmaceutical landscape.

Data-driven decisions are key in the healthcare industry. Did you know the Brazilian market is projected to grow by 9.8% this year? This surge, coupled with a complex public-private healthcare system, presents a unique opportunity for pharmaceutical companies. In our latest article, written by Dr. Fisiologia on behalf of Pharma Meeting Brazil , we discuss more about all Brazil's advantages for foreign pharmaceutical companies. Download now to read the full article here: https://lnkd.in/dMwapyDv

In the aftermath of COVID, the pharmaceutical industry is emerging from the historical perception of being a ‘laggard’ in technology adoption. Of the 132 ‘lighthouses’ accredited by the World Economic Forum to date, 19 sites are from the pharmaceutical and medical devices industry – two of them being Indian pharma companies Cipla and Dr. Reddy’s Laboratories. These achievements formed the central theme of discussion at the recently-concluded Indian Pharmaceutical Alliance's 8th Global Pharmaceutical Quality Summit, where Vikas Bhadoria, David Keeling, Maria Fernandez, and Vivek Arora shared insights on how Indian pharmaceutical companies are accelerating the adoption of digital technologies to boost quality and productivity. Read more about the discussions at IPA this year here: https://lnkd.in/gr9UVMww

In the aftermath of COVID, the pharmaceutical industry is emerging from the historical perception of being a ‘laggard’ in technology adoption. Of the 132 ‘lighthouses’ accredited by the World Economic Forum to date, 19 sites are from the pharmaceutical and medical devices industry – two of them being Indian pharma companies Cipla and Dr. Reddy’s Laboratories. These achievements formed the central theme of discussion at the recently-concluded Indian Pharmaceutical Alliance's 8th Global Pharmaceutical Quality Summit, where Vikas Bhadoria, David Keeling, Maria Fernandez, and Vivek Arora shared insights on how Indian pharmaceutical companies are accelerating the adoption of digital technologies to boost quality and productivity. Read more about the discussions at IPA this year here: https://lnkd.in/dvn5qgav

Streamline your drug development pathway In pharmaceutical development, collaborating with multiple Contract Development and Manufacturing Organisations (CDMOs) and Contract Research Organisations (CROs) poses potential hurdles - from poor communication to delays, errors, and inconsistent feedback during the progression from preclinical to formulation optimisation and clinical trials. Download our SGS guide to discover: - How to collaborate in the fast-paced world of drug development - The current challenges of working with different CDMOs and CROs - A pathway built to bring drug development consultancy, bioanalysis, formulation and manufacturing, and clinical research services into one program - How do SGS PACE regulatory consultancy services factor into the mix? Download the guide https://lnkd.in/eXKJfEgx Brought to you by SGS #DrugDevelopment #Biotechnology #Pharmaceutical

Pharmaceutical companies are uniquely positioned to make a difference by partnering with Integrated Delivery Networks (IDNs). These networks are all about enhancing patient care while keeping costs down. By sharing data and working together, pharmaceutical companies can tailor their drug development to directly address patient needs. This approach is a win-win; it isn't just good for patients, it's smart business. Interested in how these partnerships work and their benefits? Dive into the details here: https://lnkd.in/ewj-Mjv2

In the aftermath of COVID, the pharmaceutical industry is emerging from the historical perception of being a ‘laggard’ in technology adoption. Of the 132 ‘lighthouses’ accredited by the World Economic Forum to date, 19 sites are from the pharmaceutical and medical devices industry – two of them being Indian pharma companies Cipla and Dr. Reddy’s Laboratories. These achievements formed the central theme of discussion at the recently-concluded Indian Pharmaceutical Alliance's 8th Global Pharmaceutical Quality Summit, where Vikas Bhadoria, David Keeling, Maria Fernandez, and Vivek Arora shared insights on how Indian pharmaceutical companies are accelerating the adoption of digital technologies to boost quality and productivity. Read more about the discussions at IPA this year here: https://lnkd.in/g2SSjGQd

In the aftermath of COVID, the pharmaceutical industry is emerging from the historical perception of being a ‘laggard’ in technology adoption. Of the 132 ‘lighthouses’ accredited by the World Economic Forum to date, 19 sites are from the pharmaceutical and medical devices industry – two of them being Indian pharma companies Cipla and Dr. Reddy’s Laboratories. These achievements formed the central theme of discussion at the recently-concluded Indian Pharmaceutical Alliance's 8th Global Pharmaceutical Quality Summit, where Vikas Bhadoria, David Keeling, Maria Fernandez, and Vivek Arora shared insights on how Indian pharmaceutical companies are accelerating the adoption of digital technologies to boost quality and productivity. Read more about the discussions at IPA this year here: https://lnkd.in/gxpYDtXu

Sharing this insightful and thoughtful media analysis in the pharmaceutical industry. Interested in learning more and how you can leverage these findings in your work? Give me a shout!